



A common European approach to the regulatory testing of nanomaterials

The quest for generating robust regulatory relevant data

Tom van Teunenbroek 09-03-2015, Venice





Introduction to NANoREG,

context, main aims, first results and impact
Introduction to ProSafe
 main aims, expected outcome ProSafe meets NANoREG (and others)
 quest for robust regulatory relevant data



Ten years of research



- >>100 million euro investment and 10 years of research on EHS aspects of Nanomaterials
- Research on characterization, release, kinetics, mode of action etc.
- Dramatically increase of number of publications on EHS aspects.
- Still no-one can answer the question: are Nanomaterials a serious thread to environment and health?





- Cause of this frustrating conclusion
- No central coordination: it's all bottom up; "Let a 1000 flowers bloom".
- Maybe appropriate for science and innovation; but for addressing societal worries and regulatory questions its rather inefficient
- $\Box V_{Data} = R^2 EC$







- V_{RD}: Value of generated regulatory data
- Reliability of generated EHS data is unknown
- Relevance of data is questionable
- Exchangeability of data is limited (no standardized ontology, no standardized way of reporting meta data, no system for data exchange
- Comparability insufficient because of difference in
 - methods,
 - materials,
 - operating practise



NANoREG: top-down



- Experience so far indicates there is a strong need for:
- Focus on regulatory needs and not (only) scientific needs: Methods and data that can be used in a regulatory context.
- Top down approach to assure R²EC. Basic condition for linking *in vitro-in vivo, categorization, read across, etc.*
- This, in a nutshell, is the basic philosophy of NANoREG.



NANoREG Project Factsheet



- Collaboration between 66 partners from:
 - 14 EU Member States
 - 2 Associated States (CH, NO).
- Involvement of industry (individual companies, CEFIC, NIA…)
- Collaboration Agreements with: Brazil and South Korea,
- Links to ECHA, OECD, ISO
- Links to ongoing EU FP7 projects
- Ca. 50 M€, (20% EC)
- 42 months duration; Started March 2013







A common European approach to the regulatory testing of nanomaterials



S

[www.nanoreg.eu]



Specific NANoREG Objectives

 Provide regulators with a set of tools for risk assessment and decision making instruments for the short to medium term, by gathering data and performing pilot risk assessment, including exposure monitoring and control, for a selected number of nanomaterials used in products,

- Develop for the long term, new characterization and testing strategies adapted to a high number of nanomaterials where many factors can affect their environmental and health impact, and
- Establish a close collaboration among authorities and industry with regard to the knowledge required for appropriate risk management, and create the basis for common approaches, mutually acceptable datasets and risk management practices.





The **Regulatory Questions** have been refined (after a round of consultation) to focus on:

- measurement, characterisation, identification,
- transformation,
- dose metrics, metrological aspects,
- persistence and long term effects,
- kinetics,
- grouping,
- hazard, risk,
- exposure, etc.

Public version of Deliverable available








Version 1.0 Date: 5 May, 2014 Keld Alstrup Jensen (WP2) Hugues Crutzen (WP1) and Aart Dijkzeul (WP8) Commented and approved by the Management Committee.

This project is funded by the EU Framework 7 Programme, contract no 310584.









 Aimed at obtaining reliable, comparable and exchangable data

Funded by The European Union



What has been achieved so far? - 3

NAN SREG

A common European approach to the regulatory testing of nanomaterials

 19 manufactured nanomaterials (supplied by industry) and additional alternative materials have been selected for mandated (!) use by NANoREG partners

Type of MNM	MNM Identification codes used by NANoREG
Titanium Dioxide	NM101, NM102, NM103
Silicon Dioxide	NM200, NM203
Zinc Oxide	NM110, NM111
Cerium Dioxide	NM212
Barium Sulphate	NM220
Silver	NM300K, NM302
Nanotubes (single and multi-walled)	NM400, NM401, NM410
Nanofibrillar cellulose	NFC Fine, NFC Medium-coarse, UPM Biofibrils
	AS, UPM Biofibrils NS, UPM Bleached Birch Pulp
Final material closing knowledge gaps	Under evaluation





 SOPs for the creation of MNM dispersions for measurement and toxicity testing have been set and prescribed

Type of test	Protocol
Defining conditions for Ultrasound bath	Calorimetic method combined with adjustment using the NM400 and NM401a as benchmark materials
Defining conditions for Probe-sonication	Calorimetic method combined with adjustment using the NM200 benchmark material
In vitro studies	NANOGENOTOX
In vivo studies	NANOGENOTOX or ENPRA
Eco-toxicity studies	PROSPECT as the basis and a NOM-water protocol for CNT





 Minimum characterisation requirements for the toxicological studies have been set and prescribed, and

3.2 Minimum characterization requirements for dispersions and exposure media

3.2.1 Test item preparation and exposure characterization protocols

To ensure high-quality assessment of the in-use performance of the dispersion protocols, *in vitro* and eco-toxicological test results, and finally to catch the potential outliers, the MC has decided on the means to produce a limited set of mandatory characterization data and how they should be reported.

The minimum characterization requirements are:

- Analysis of the hydrodynamic size(-distribution) of NM in the batch dispersion.
- Analysis of the initial hydrodynamic size(-distribution) of NM in the exposure medium.
- Analysis of the final hydrodynamic size(-distribution) in the exposure medium.

[excerpt from NANoREG Guidance Document]





... and what else are we doing:

Most of planned R&D activities are pending; e.g.

- Characterisation of NMs; SOPs for primary particle size, VSSA, evaluation OECD TGs,
- (Critical) exposure scenarios, dustiness testing, exposure measurements, mesocosms, minimum characterisation requirements
- Long term inhalation study, prenatal study, in vivo genotoxicity and immune study
- (Preparatory work for) in vitro testing, comet assay,

... and much more





Coordination and support action H2020

- Startdate: 1 February 2015
- Duration: 2 years
- 11 Partners plus Strategic Policy Development Group
- Main aim: coordination and strengthening existing and new initiatives on the field of nanosafety in a regulatory context FP7 & H2020, OECD, ECHA, EU-US.






- White Paper: broadly accepted document; basis for regulator and industry to cover EHS aspects of Nms including SbD
 - Evaluation of the OECD WPMN sponsorship programme and NANoREG I.
 - Acceptance of the NANoREG safe innovation and safe-by-design concept
- Long term research goals (2015 2020 and 2020 - 2025) inclusive funding arrangements for EU-US research collaboration



Relations ProSafe








ProSafe supporting NANoREG








ProSafe influencing Safe by Design

ProSafe





ProSafe brings together



- NANoREG results:
 - Regulatory framework
 - Toolbox
- Safe by design (NANoREG and NANoREG II)
- Results evaluation OECD data
- Results other projects

